Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Clinical Study on Savolitinib + Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic NSCLC (SANOVO)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05009836
Recruitment Status : Not yet recruiting
First Posted : August 18, 2021
Last Update Posted : August 18, 2021
Sponsor:
Information provided by (Responsible Party):
Hutchison Medipharma Limited

Brief Summary:
A Phase III Clinical Study on Savolitinib Combined with Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic Non-small Cell Lung Cancer

Condition or disease Intervention/treatment Phase
Non-small Cell Lung Cancer Drug: Savolitinib Drug: Placebo Phase 3

Detailed Description:
A Multicenter, Randomized, Double-blind, Phase III Clinical Study to Evaluate the Efficacy and Safety of Savolitinib Combined with Osimertinib versus Placebo Combined with Osimertinib as the First-line Therapy for Patients with EGFRm+/MET+ Locally Advanced or Metastatic Non-small Cell Lung Cancer

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 320 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description:

This study plans to enroll 320 patients, and eligible patients will be randomized in a ratio of 1:1 into the following treatment groups using central randomization system (IWRS): • Study group: Savolitinib 600 mg or 400 mg QD orally + Osimertinib 80 mg QD orally

• Control group: placebo 600 mg or 400 mg QD orally + Osimertinib 80 mg QD orally

Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Multicenter, Randomized, Double-blind, Phase III Clinical Study to Evaluate the Efficacy and Safety of Savolitinib + Osimertinib Versus Placebo + Osimertinib as the First Line Therapy for Patients With EGFRm+/MET+ NSCLC
Estimated Study Start Date : August 31, 2021
Estimated Primary Completion Date : November 15, 2024
Estimated Study Completion Date : January 31, 2025

Resource links provided by the National Library of Medicine

Drug Information available for: Osimertinib

Arm Intervention/treatment
Experimental: Savolitinib
Savolitinib 600 mg or 400 mg QD orally +Osimertinib 80 mg QD orally ( every 3 weeks)
Drug: Savolitinib
Subjects will receive Savolitinib orally once per day (QD) + Osimertinib orally QD,21day cycles (every 3 weeks) until disease progression, death, adverse event (AE) leading to discontinuation or withdrawal of consent.
Other Name: HMPL-504

Placebo Comparator: placebo
placebo 600 mg or 400 mg QD orally+ Osimertinib 80 mg QD orally ( every 3 weeks)
Drug: Placebo
Subjects will receive placebo orally once per day (QD) + Osimertinib orally QD,21day cycles (every 3 weeks) until disease progression, death, adverse




Primary Outcome Measures :
  1. PFS [ Time Frame: 17 months after the last patient enrolled ]
    Progression-free survival (PFS) using Investigator assessment as defined by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1)


Secondary Outcome Measures :
  1. Safety and tolerability [ Time Frame: 17 months after the last patient enrolled ]
    Incidence and nature of treatment emergent adverse events (TEAE), the other safety variables including physical examination, vital signs and laboratory examinations

  2. The objective response rate of the tumor (ORR) [ Time Frame: 17 months after the last patient enrolled ]
    the incidence of confirmed complete response or partial response

  3. The disease control rate (DCR) [ Time Frame: 17 months after the last patient enrolled ]
    the incidence of complete response, partial response and stable disease

  4. Duration of Response (DoR) [ Time Frame: 17 months after the last patient enrolled ]
    the duration between the date the criteria for complete response or partial response was first measured (first record shall prevail) and the date of disease recurrence or progression as objectively recorded

  5. Overall survival (OS) [ Time Frame: 17 months after the last patient enrolled ]
    the time from the date of randomization to the date of death (all causes)

  6. Time to Response (TTR) [ Time Frame: 17 months after the last patient enrolled ]
    the period from the date of randomization to the date when the criteria for complete response or partial response was first measured (first record shall prevail).

  7. PFS [ Time Frame: 17 months after the last patient enrolled ]
    Progression-free survival (PFS) using IRC as defined by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1)

  8. Development of diagnostic technology [ Time Frame: 17 months after the last patient enrolled ]
    The residual samples may be used for development of MET Companion Diagnostics (CDx)



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   28 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Gender Based Eligibility:   Yes
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Fully aware of this study and voluntary to sign the informed consent form, and being willing and able to comply with the study procedure;
  2. Age ≥ 18
  3. In accordance with the Eighth Edition of TNM Staging of Lung Cancer by the International Association for the Study of Lung Cancer and American Joint Committee on Cancer, and patients with histologically or cytologically confirmed unresectable locally advanced (stage ⅢB/ⅢC), metastatic or recurrent (stage IV) NSCLC who are not suitable for radical concurrent chemoradiotherapy;
  4. Carrying two common EGFR mutations clearly related with the sensitivity to EGFR-TKI (i.e., exon 19 deletion, and L858R) and c-MET overexpression
  5. Having measurable lesions (in accordance with RECIST 1.1 criteria);
  6. ECOG Performance Status score 0 or 1, or Karnofsky score ≥80;
  7. Survival is expected to exceed 12 weeks;
  8. No any previous systematic antitumor therapy for advanced/metastatic disease;
  9. adequate bone marrow reserve or organ function
  10. Female patients of childbearing potential must agree to use effective contraceptive methods from screening period to 4 weeks after discontinuation of the study drug 11. Male patients whose sexual partners are women of childbearing potential must use condoms during sexual intercourse during the study and within 6 months after discontinuation of study drug

12. Being able to take or swallow the drug orally.

Exclusion Criteria:

  1. Previous treatment with EGFR inhibitors or MET inhibitors;
  2. Currently having other malignant tumors, or having other infiltrating malignant tumors in the past 5 years
  3. Antitumor therapy within 2 weeks prior to the start of study treatment, including hormone therapy, biotherapy, immunotherapy or the traditional Chinese medicine for antitumor indication;
  4. Having received extensive radiotherapy (including radionuclide therapy, e.g., Sr-89) within 4 weeks prior to the start of study treatment or palliative local radiotherapy within one week prior to the start of study treatment, or the above adverse reactions of radiotherapy did not recover;
  5. Having received a major surgery within 4 weeks prior to the start of study treatment or a minor surgery (except biopsy, and venous catheterization) within one week prior to the start of study treatment;
  6. Currently receiving the potent CYP3A4 inducers or potent CYP1A2 inhibitors within two weeks prior to the start of study treatment;
  7. Having not been sufficiently recovered from the toxicity and/or complication resulting from any interventional measure prior to the start of treatment;
  8. Clinically significant active infection, including but not limited to tuberculosis, human immunodeficiency virus (HIV) infection (positive HIV1/2 antibody);
  9. Active hepatitis B, or active hepatitis C;
  10. Acute myocardial infarction, unstable angina pectoris, stroke or transient ischemic attack;
  11. Uncontrollable hypertension despite the use of drugs,
  12. Mean resting corrected QT interval (QTcF) or Any important abnormality in rhythm;
  13. Patients whose known cancerous thrombus or deep vein thrombosis are stable for ≥2 weeks after receiving treatment with low molecular weight heparin (LMWH) or analogues with similar efficacy can be enrolled;
  14. Any important abnormality in rhythm
  15. Presence of meningeal metastasis, spinal cord compression or active brain metastasis prior to the start of study treatment.
  16. Known allergy to the active or inactive ingredient of Savolitinib or Osimertinib;
  17. Lack of compliance with participation in this clinical study or inability to comply with the limitations and requirements of the study, as judged by investigators;
  18. Having participated in other drug clinical trials and received the study drug within 3 weeks prior to the start of study treatment; 19. Known allergy to the active or inactive ingredient of Savolitinib or Osimertinib; 20. Previous history of interstitial lung diseases, drug-induced interstitial lung diseases, radiation pneumonitis requiring glucocorticoid therapy and any active interstitial lung diseases; 21. Pregnant and lactating women; 22. Any other disease, metabolic abnormality, physical examination abnormality or laboratory examination abnormality, certain disease or state, based on which there is a reason to suspect that the subject is not suitable for the study drug, or one condition that will affect intepretaton of the study results or put the subject at high risk.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05009836


Contacts
Layout table for location contacts
Contact: Lu Chen +86 021 -20673000 ext 5014 Luc@hutch-med.com

Sponsors and Collaborators
Hutchison Medipharma Limited
Investigators
Layout table for investigator information
Principal Investigator: Yilong Wu, MD Guangdong Provincial People's Hospital
Layout table for additonal information
Responsible Party: Hutchison Medipharma Limited
ClinicalTrials.gov Identifier: NCT05009836    
Other Study ID Numbers: 2020-504-00CH4
First Posted: August 18, 2021    Key Record Dates
Last Update Posted: August 18, 2021
Last Verified: July 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma, Non-Small-Cell Lung
Carcinoma, Bronchogenic
Bronchial Neoplasms
Lung Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Respiratory Tract Diseases